Evelo Biosciences is dissolving. One month after starting a search for strategic alternatives, the Flagship Ventures-backed microbiome biotech has found its only option is to close its doors and hand any cash to creditors.
- Primary endpoint was not achieved “ - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE)...
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon...
Circling Back On Evelo Biosciences
Evelo Biosciences enters into termination and surrender pact with Bio-Rad
Moderna Co-Founder's Firm Bought Up This Embattled Biotech Stock
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE...
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered...
“ EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 “ CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical...
Evelo Biosciences Provides Clinical Updates